undamentalytics Newsletter
Sign in

X4 Pharmaceuticals, Inc balance sheet

At the end of fiscal 2025, X4 Pharmaceuticals, Inc had total assets of $290m, total liabilities of $104m and shareholders' equity of $186m. It held $217m in cash against $75.0m of debt: net cash of $142m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents812679821229956217195
Receivables—0———0112
Inventory—————03——
Total current assets91298388129122112262219
Goodwill02727171717171717
Total assets10161123117156147146290253
Accounts payable323489964
Deferred revenue (current)——————001
Total current liabilities8912142223332619
Short-term debt200110———
Long-term debt82033333255757575
Total debt102033343455757575
Total liabilities22315053829612410498
Shareholders' equity−771297364745122186155
Non-controlling interests and other (assets − liabilities − equity)65————————
Net debt (negative = net cash)2−106−46−48−88−4419−142−120
Shares outstanding14m—————6m—96m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: KROS vs XFORALEC vs XFORPRQR vs XFOR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from X4 Pharmaceuticals, Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to X4 Pharmaceuticals, Inc.